100 VANGUARD BOULEVARD,
MALVERN , PA, 19355

Rank

Rank Universe

Summary

The fund seeks to track the total return performance of a benchmark index before fees and expenses by investing in companies across any size outside the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

Next, the research team focuses on stocks issued by companies l More

Link

Directors

Jan 11, 2024
  • Peter F. Volanakis
  • Sarah Bloom Raskin
  • Andre F. Perold
  • Emerson U. Fullwood
  • David Thomas
  • Mortimer J. Buckley
  • Tara Bunch
  • Deanna Mulligan
  • Grant Reid
  • F. Joseph Loughrey
  • Scott C. Malpass
  • Mark Loughridge

Chief Compliance Officer

  • Jacqueline Angell

Fund Manager(s)

  • Justin Hales
  • Christine Franquin

Price

  • $ 35.97 ( +0.04 )
    Nov 4, 2024
    Last Close
  • Net Assets
  • $24.1B
    Apr 1, 2024
  • Holding
  • 95
    Sep 27, 2024
    More

  • 52-Week High/Low
  • $38.27 - $30.83
  • Turnover
  • 3.1%
  • Expense Ratio
  • 0.09%

Company Name

Holding

Novartis AG 1.82 %
Lonza Group AG 0.38 %
Experian PLC 0.35 %
Wolters Kluwer NV 0.32 %
Volvo AB 0.31 %
Adyen NV 0.29 %
Nordea Bank Abp 0.25 %
NatWest Group PLC 0.24 %
Air Liquide SA 0.24 %
STMicroelectronics NV 0.17 %
More 0.17 %

Documents

Prospectus

Annual Reports

Performance

YTD

2.6%

3 Year

-3.31%

5 Year

19.82%

Best

38.92%

2003

Worst

-44.66%

2008

Alpha

VESIX S&P 500

Chart +